CPRX logo

CPRXCatalyst Pharmaceuticals Inc

$31.22
$0.01
(0.03%)
Today
Closed $31.28
$0.0591
(0.19%)
After Hours
Updated: 07:54 PM EDT
Reported EarningsMay 11
Mkt Cap$3.83B
Vol1.74M
News
all
press releases
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
More News
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
News Placeholder
CPRX or UTHR: Which Is the Better Value Stock Right Now?
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Zacks
News Placeholder
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 12, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
News Placeholder
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
News Placeholder
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +23.44% and +1.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX...
Business Wire
News Placeholder
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to...
PR Newswire
<
1
2
...
>